Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that data from the ongoing Phase 1b study of R2891, a potent and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback